Literature DB >> 21649801

A study of variations in the reported haemophilia B prevalence around the world.

J S Stonebraker1, P H B Bolton-Maggs, J Michael Soucie, I Walker, M Brooker.   

Abstract

The objectives of this article were to study the reported prevalence of haemophilia B (HB) on a country-by-country basis and to analyse whether the prevalence of HB varied by national economy. The prevalence of HB is the proportion of diagnosed, reported cases of HB in a population at a specific point of time. We collected data on the HB prevalence for 105 countries from the World Federation of Hemophilia annual global surveys. Our results showed that the HB prevalence varied considerably among countries, even among the wealthiest of countries. The HB prevalence (per 100 000 males) for the highest income countries was 2.69 ± 1.61 (mean ± SD), whereas the prevalence for the rest of the world was 1.20 ± 1.33 (mean ± SD). Ireland had the highest reported HB prevalence of 8.07 per 100 000 males. There was a strong trend of increasing HB prevalence (per 100 000 males) over time. Prevalence data reported from the WFH compared well with prevalence data from the literature. The WFH annual global surveys have some limitations, but they are the best available source of worldwide haemophilia data. Prevalence data are extremely valuable information for the planning efforts of national healthcare agencies in setting priorities and allocating resources for the treatment of HB.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21649801     DOI: 10.1111/j.1365-2516.2011.02588.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  26 in total

1.  Clinical utility gene card for: haemophilia B.

Authors:  Peter Vincent Jenkins; Catriona Keenan; Steve Keeney; Tony Cumming; James S O'Donnell
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

2.  Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.

Authors:  Sven Björkman; Victor Ahlén
Journal:  Eur J Clin Pharmacol       Date:  2012-01-27       Impact factor: 2.953

Review 3.  The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Giancarlo M Liumbruno; Massimo Franchini; Pier Mannuccio Mannucci; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  STALing B cell responses with CD22.

Authors:  Craig P Chappell; Edward A Clark
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

5.  Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data.

Authors:  A Iorio; J S Stonebraker; M Brooker; J M Soucie
Journal:  Haemophilia       Date:  2016-12-08       Impact factor: 4.287

Review 6.  The European Haemophilia Network (EUHANET).

Authors:  Michael Makris; Gabriele Calizzani; Kathelijn Fischer; Alexander Gatt; Estelle Gilman; Robert Hollingsworth; Thierry Lambert; Riitta Lassila; Pier Mannuccio Mannucci; Flora Peyvandi; Jerzy Windyga
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

7.  Mutation Spectrum and Genotype-Phenotype Analyses in a Pakistani Cohort With Hemophilia B.

Authors:  Muhammad Tariq Masood Khan; Arshi Naz; Jawad Ahmed; Tahir Shamsi; Shariq Ahmed; Nisar Ahmed; Ayisha Imran; Nazish Farooq; Muhammad Tariq Hamayun Khan; Abid Sohail Taj
Journal:  Clin Appl Thromb Hemost       Date:  2017-07-28       Impact factor: 2.389

Review 8.  Delivery and neuraxial technique outcomes in patients with hemophilia and in hemophilia carriers: a systematic review.

Authors:  Brandon M Togioka; Richard M Burwick; Jody L Kujovich
Journal:  J Anesth       Date:  2021-03-08       Impact factor: 2.078

9.  The European standards of Haemophilia Centres.

Authors:  Paul Giangrande; Gabriele Calizzani; Ivana Menichini; Fabio Candura; Pier Mannuccio Mannucci; Michael Makris
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

10.  The Italian institutional accreditation model for Haemophilia Centres.

Authors:  Gabriele Calizzani; Fabio Candura; Ivana Menichini; Romano Arcieri; Giancarlo Castaman; Alessandro Lamanna; Maria R Tamburrini; Antonio Fortino; Monica Lanzoni; Samantha Profili; Simonetta Pupella; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.